cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.6084/m9.figshare.27956919
title: PLADA Database

description: A human movement experiment was conducted with 4 young adults who performed 3 walking tests at a constant speed of 2 mph. PLADA-instrumented templates are used to record the plantar load of the lower extremities during walking, synchronized with the motion capture system that records the angular trajectories of the lower extremity joints.In this shared data repository, the kinematic and kinetic synchronized data is provided considering the local time of acquisition. In addition, the processed data are provided considering step segmentation and normalization by percentage of the gait cycle.Description of the data set structure:Data.Info: general information of the participant.Data.TrialX:Left: Data recorded in the left template.Right: Data recorded in the right template.KinematicLeft: Recorded data of left articulation angles.KinematicRight: angle data.Step:KineticLeft: the pressure at 24 FSR and GRF normalizes by the gait cycle .KineticRight: pressure to 24 FSR and GRF normalize by gait cycle.KinematicLeft: The angles of the joints are normalized by the gait cycle.KinematicRight: The angles of the joints are normalized by the walking cycle.<br>
DOI: 10.5281/zenodo.14276489
title: MLOps in Practice: Requirements and a Reference Architecture from Industry

description: This repository includes the replication package of our grey literature review  and interview-based study on MLOps: requirements and architectures.

1. ***MLOPs.atlproj***   Grounded Theory (codes, groupings and analysis) was performed using the Atlas.ti tool for qualitative data analysis2. ***MLOpsReq.pdf***   Mapping between requirements and sources3. ***Source_Table.pdf***   A summary and meta-data of sources used   3. ***GLR_methodology.png***   The gray literature review methodology flowchart   4. ***Survey_Answers.xlsx***   The questionnaire and answers from six MLOps experts5. ***Interviews***   The scanned images of the notes taken during the interviews 7. ***Approval letter ERB2024JADS13.pdf***   ERB approval letter for interview-based study
DOI: 10.5281/zenodo.14276490
title: MLOps in Practice: Requirements and a Reference Architecture from Industry

description: This repository includes the replication package of our grey literature review  and interview-based study on MLOps: requirements and architectures.

1. ***MLOPs.atlproj***   Grounded Theory (codes, groupings and analysis) was performed using the Atlas.ti tool for qualitative data analysis2. ***MLOpsReq.pdf***   Mapping between requirements and sources3. ***Source_Table.pdf***   A summary and meta-data of sources used   3. ***GLR_methodology.png***   The gray literature review methodology flowchart   4. ***Survey_Answers.xlsx***   The questionnaire and answers from six MLOps experts5. ***Interviews***   The scanned images of the notes taken during the interviews 7. ***Approval letter ERB2024JADS13.pdf***   ERB approval letter for interview-based study
DOI: 10.15468/dl.uehqde
title: Occurrence Download

description: A dataset containing 139 species occurrences available in GBIF matching the query:
{
 "and" : [
 "GadmGid is DEU.11_1",
 "OccurrenceStatus is Present",
 "TaxonKey is Procyon lotor (Linnaeus, 1758)",
 "Year 2019-2024"
 ]
}

 The dataset includes 139 records from 6 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0017294-241126133413365/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.cs42mu
title: Occurrence Download

description: A dataset containing 10026 species occurrences available in GBIF matching the query:
{
 "and" : [
 "TaxonKey is Mora moro (Risso, 1810)",
 "HasCoordinate is true",
 "HasGeospatialIssue is false"
 ]
}

 The dataset includes 10026 records from 56 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0017293-241126133413365/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.qg8u5m
title: Occurrence Download

description: A dataset containing 3 species occurrences available in GBIF matching the query:
{
 "and" : [
 "TaxonKey is Balaenoptera brydei Olsen, 1913",
 "Geometry POLYGON((170 20, 170 50, 120 50, 120 20, 170 20))",
 "HasCoordinate is true"
 ]
}

 The dataset includes 3 records from 2 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0017295-241126133413365/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.5281/zenodo.7674867
title: On the influence of bed roughness on saltation in inertial regime

description: Matlab files containing jumps (hops) features (measurement done via Tracker software, image analysis) by columns: 1/ hop length, 2/ hop height, 3/ horizontal rebund velocity, 4/ vertical rebund velocity, 5/ horizontal impact velocity, 6/ vertical impact velocity, 7/ horizontal impact velocity at the end of the jump, 8/ vertical impact velocity at the end of the jump, 9/ rebund angle, 10/ impact angle, 11/ impact angle at the end of the jump. Original videos available on request (very large files).
description: The work was supported by ANR FEM project PHYSIC (ANR-10-IEED-0006-10) and by ISblue project, Interdisciplinary graduate school for the blue planet  (ANR-17-EURE-0015) and co-funded by a grant from the French government under the program "Investissements d'Avenir" embedded in France 2030. G.M. is particularly grateful to the "granular team" from IPR for their help during the laboratory experiment.
DOI: 10.5281/zenodo.7674868
title: On the influence of bed roughness on saltation in inertial regime

description: Matlab files containing jumps (hops) features (measurement done via Tracker software, image analysis) by columns: 1/ hop length, 2/ hop height, 3/ horizontal rebund velocity, 4/ vertical rebund velocity, 5/ horizontal impact velocity, 6/ vertical impact velocity, 7/ horizontal impact velocity at the end of the jump, 8/ vertical impact velocity at the end of the jump, 9/ rebund angle, 10/ impact angle, 11/ impact angle at the end of the jump. Original videos available on request (very large files).
description: The work was supported by ANR FEM project PHYSIC (ANR-10-IEED-0006-10) and by ISblue project, Interdisciplinary graduate school for the blue planet  (ANR-17-EURE-0015) and co-funded by a grant from the French government under the program "Investissements d'Avenir" embedded in France 2030. G.M. is particularly grateful to the "granular team" from IPR for their help during the laboratory experiment.
DOI: 10.15468/dl.g8kjvv
title: Occurrence Download

description: A dataset containing 39 species occurrences available in GBIF matching the query:
{
 "and" : [
 "TaxonKey is Nibea mitsukurii (Jordan & Snyder, 1900)",
 "Geometry POLYGON((170 20, 170 50, 120 50, 120 20, 170 20))",
 "HasCoordinate is true"
 ]
}

 The dataset includes 39 records from 9 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0017297-241126133413365/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.58020/g2nf-m919
title: A Phase I/IIa Trial of Intravenous Immunoglobulin (IVIG) Therapy Following Portoenterostomy in Infants with Biliary Atresia

description: The PRIME study was a multicenter prospective phase I/IIA open label trial, aimed at assessing the feasibility, tolerability, and safety of intravenous immunoglobulin (IVIG) therapy following hepatic portoenterostomy (HPE) in infants with biliary atresia (BA). After enrollment, participants received three intravenous doses of IVIG at designated intervals over the first 60 days following HPE and were followed for 360 days. All infants in this trial were also treated with standardized doses of other routine standard-of-care treatments for BA and this routine clinical care was not modified by participation in this study.
DOI: 10.58020/1dtq-b663
title: Biliary Atresia Study in Infants and Children

description: The Childhood Liver Disease Research Network (ChiLDReN) is a consortium committed to research into the etiology, pathogenesis, and treatment of rare pediatric liver diseases. Biliary atresia, one disorder studied by the consortium, is characterized by destruction or discontinuity of the extrahepatic biliary system, which results in obstruction to bile flow. Little is known about either the cause of biliary atresia or the factors that influence disease progression. The Biliary Atresia Study in Infants and Children (BASIC) is a prospective, observational study that was established by ChiLDReN to collect pertinent clinical information and biospecimens to aid in the understanding of the disorder. Specific aims of the study include identifying the gene(s) implicated in the etiology of biliary atresia, identifying the polymorphisms that may influence disease progression, and characterizing the natural history of the older, non-transplanted patients with biliary atresia.

Patients between the ages of 6 months and 20 years with a confirmed diagnosis of biliary atresia are eligible to participate in the study. Following enrollment, participants are separated into two cohorts: those who have their native liver and those who have received a liver transplant. Clinical information, including medical history, and biospecimens are collected at baseline. Those with their native liver will have clinical information collected annually up to 20 years of age. Genetic analyses are performed on the biospecimens provided to identify the gene(s) and polymorphisms implicated in the etiology and progression of biliary atresia.
DOI: 10.58020/e7qc-j633
title: Clinical Trial of Entecavir/Pegylated Interferon in Immune Tolerant Children with Chronic Hepatitis B Virus Infection

description: The Clinical Trial of Entecavir/Pegylated Interferon in Immune Tolerant Children With Chronic HBV Infection (HBRN Immune Tolerant P) sought to determine the safety and efficacy of treatment using a combination of drugs (entecavir and pegylated interferon) in children ages 3-<18 years old with immunotolerant chronic hepatitis B. Children age 3-<18 years with immunotolerant chronic hepatitis B (CHB) infection who fulfilled the entry criteria received entecavir as monotherapy for 8 weeks and then combination therapy with entecavir and pegylated interferon by weekly subcutaneous injection until week 48. Children were to be followed for 48 weeks after discontinuation of therapy.
DOI: 10.58020/z6wg-1649
title: Biomarker Collection and Analysis in the Prevention of Serious Adverse Events Following Angiography (PRESERVE) Trial Cohort

description: The intravascular administration of iodinated contrast media for diagnostic imaging is a common cause of acute kidney injury (AKI) and a leading cause of iatrogenic renal disease. Contrast-induced AKI is associated with serious adverse outcomes including death, need for dialysis, prolonged hospitalization, and acceleration in the rate of progression of underlying chronic kidney disease. The benefit of IV isotonic bicarbonate compared to IV isotonic saline and of N-acetylcysteine for the prevention of contrast-induced AKI and associated adverse outcomes remains unclear. The purpose of the PRESERVE trial was to compare the effectiveness of IV isotonic sodium bicarbonate with IV isotonic sodium chloride and oral NAC with placebo for the prevention of serious adverse outcomes in high-risk participants scheduled to undergo coronary or non-coronary angiography.

The Biomarker Collection and Analysis sub-study collected, banked, and analyzed the blood and urine of participants from the VA-funded PRESERVE trial. Blood and urine proteins and other markers may predict the development of contrast-induced acute kidney injury and diagnose the very early stages of this condition following angiography. In addition, these biomarkers may predict which patients that develop acute kidney injury following angiography are likely to experience serious longer-term complications such as death, need for dialysis, and/or progressive loss of kidney function.
DOI: 10.58020/w5sp-c981
title: Combination Entecavir and Peginterferon Therapy in HBeAg-Positive Immune-Tolerant Adults with Chronic Hepatitis B

description: The Hepatitis B Research Network Combination Entecavir and Peginterferon Therapy in HBeAg-Positive Immune-Tolerant Adults with Chronic Hepatitis B (HBRN Immune Tolerant A) study sought to determine the efficacy of treatment with 8 weeks of entecavir followed by 40 weeks of both entecavir and peginterferon in the treatment of chronic hepatitis B in hepatitis B “e” antigen (HBeAg) positive adults who were in the immune tolerant phase. Additionally, the study evaluated the safety and sustained responses after treatment with entecavir and peginterferon alfa-2a in the treatment of chronic hepatitis B in HBeAg positive adults in the immune tolerant phase.
DOI: 10.58020/n7th-m611
title: Combination Therapy of Peginterferon Alfa-2a and Tenofovir versus Tenofovir Monotherapy in HBeAg-positive and HBeAg-negative Chronic Hepatitis B

description: The Combination Therapy of Peginterferon Alfa-2a and Tenofovir versus Tenofovir Monotherapy in HBeAg-positive and HBeAg-negative Chronic Hepatitis B (HBRN Immune Active) study sought to compare the long-term efficacy of combination therapy with peginterferon plus tenofovir versus tenofovir monotherapy in the treatment of chronic hepatitis B. This randomized (1:1) parallel group trial compared (i) tenofovir disoproxil fumarate (TDF) 300 mg daily for 192 weeks (4 years) and (ii) peginterferon (PegIFN) alfa-2a 180 µg weekly for 24 weeks plus TDF 300 mg daily for 192 weeks (4 years). Enrolled participants were stratified by HBeAg status (positive/negative), genotype (A versus all others), and cirrhosis (present versus absent). After 192 weeks of treatment, participants meeting criteria for treatment discontinuation stopped treatment and were followed for 48 weeks (total duration of treatment and follow up was 240 weeks). Emtricitabine/tenofovir coformulated as Truvada, approved for treatment of HIV but not for treatment of hepatitis B virus (HBV) infection, was offered to patients with primary nonresponse, partial virological response, or confirmed virologic breakthrough.
DOI: 10.58020/3n9t-sg63
title: Efficacy and Safety of the Intestinal Bile Acid Transport (IBAT) Inhibitor LUM001 in the Treatment of Pruritus in Alagille Syndrome Patients

description: The ITCH study was a randomized, double-blind, placebo-controlled, parallel group, multi-center study in children with Alagille syndrome (ALGS). The study was designed to investigate the effects of LUM001 (Maralixibat), compared to placebo, on pruritus, serum bile acids, liver enzymes, and other biochemical markers associated with cholestatic liver disease, following daily dosing over a 13-week period.
DOI: 10.58020/tthh-e971
title: Immune Regulation and Costimulation in Natural History and Therapeutic Outcome of Chronic Hepatitis B

description: Hepatitis B, a significant cause of cirrhosis and hepatocellular carcinoma worldwide, affects an estimated 800,000 to 1.4 million people in the United States. Liver disease pathogenesis and viral clearance in hepatitis B virus (HBV) infection is believed to be immune-mediated, defined by distinct patterns of immune effector and regulatory responses. The Immune Regulation and Costimulation in Natural History and Therapeutic Outcome of Chronic Hepatitis B study was designed to examine the effects of antiviral therapy in host immune phenotype and to investigate if antiviral immune responses before, during, and after therapy can predict long term therapeutic response. This study is ancillary to two clinical trials conducted by the Hepatitis B Research Network, titled Combination Therapy of Pegylated Interferon Alfa-2a and Tenofovir Versus Tenofovir Monotherapy in Chronic Hepatitis B and Combination Entecavir and Peginterferon Therapy in HBeAg-Positive Immune-Tolerant Adults With Chronic Hepatitis B. It is hypothesized that therapeutic HBV suppression will enhance antiviral immune effector responses and reduce immune inhibitory factors in participants with chronic hepatitis B.

Participants for the Immune Regulation and Costimulation study are recruited from individuals who are enrolled in the HBRN clinical trials of adults with chronic hepatitis B. Immune regulatory and effector responses relative to serum HBV DNA, alanine aminotransferase (ALT), and clinical outcome are assessed as primary outcome measures. Specifically, IFN-gamma and IL 10 responses, T cell activation and costimulatory markers (PD1, CTLA4, CD28, CD127), FoxP3+ Treg frequency, dendritic cell frequency, and NK frequency are evaluated as measures of immune response. These measures are evaluated throughout the course of the two clinical trials until the termination of the treatment studies.
DOI: 10.58020/n50b-rk65
title: Immune Regulation and Costimulation in Natural History of Chronic Hepatitis B

description: Hepatitis B, a significant cause of cirrhosis and hepatocellular carcinoma worldwide, affects an estimated 800,000 to 1.4 million people in the United States. While progress has been made in the prevention, diagnosis, and treatment of chronic hepatitis B, challenges remain in identifying persons affected by the virus and in determining recommendations for management and treatment. The Hepatitis B Research Network (HBRN) was a multicenter network to investigate the etiology and progression of the disease, and to test the safety and efficacy of current treatment approaches. 

Hepatitis B virus (HBV) is largely a non-cytopathic virus. Therefore, liver disease pathogenesis and viral clearance in HBV infection is believed to be immune-mediated. At the same time, HBV persists with impaired antiviral immune effector responses that are potentially regulated by multiple immune pathways, including the CD28 costimulatory receptors and immune regulatory T cells. The Immune Regulation and Costimulation in Natural History of Chronic Hepatitis B (HBRN Immunology Cohort) study aimed to assess whether the balance between immune regulatory and effector responses in HBV-infected individuals defines the level of viremia, liver inflammation, and treatment outcomes.
DOI: 10.58020/0wdb-0v82
title: Lifestyle Interventions for Expectant Moms

description: Studies have shown that overweight and obese women are at increased risk for several complications of pregnancy, including gestational diabetes mellitus, hypertension, preeclampsia, and cesarean delivery. Additionally, the children of overweight or obese pregnant women show an increased risk of prematurity, congenital anomalies, and childhood obesity. The Lifestyle Interventions for Expectant Mothers (LIFE-Moms) consortium was a network of seven clinical centers and a data coordinating center to identify effective behavioral and lifestyle interventions that improve weight, glycemic control, and outcomes in obese and overweight pregnant women and their children. 

Participants were randomized between 9 weeks 0 days and 15 weeks 6 days gestation, and followed through one-year postpartum. Standardized measures were collected throughout gestation: at baseline (9-15 weeks), 24-27 weeks, 35-36 weeks, delivery, and one-year postpartum. Eligibility criteria, specific outcome measures, and assessment procedures were standardized across trials. Measures that were collected in all seven trials were defined as ‘core’ data and measures collected by four to six trials were defined as ‘super-shared’ data. All core and super-shared measures had a standardized definition and/or detailed procedures to facilitate uniform collection, a standardized training and certification process, and were entered into a common dataset at the data coordinating center.
DOI: 10.58020/kgny-bv08
title: Longitudinal Assessment of Transient Elastography in Cystic Fibrosis

description: Noninvasive monitoring of liver fibrosis is an unmet critical need in cystic fibrosis (CF) liver disease. Liver biopsy is infrequently used in CF due to the patchy nature of liver involvement and is not suitable for longitudinal studies of progressive liver disease in CF. Indeed, unlike many other liver diseases, synthetic dysfunction is rare in CF liver disease. Portal hypertension due to hepatic fibrosis mediates most if not all of the complications seen in CF liver disease.

The Longitudinal Assessment of Transient Elastography in Cystic Fibrosis (ELASTIC-CF) study assessed if combining FibroScan® measurement of liver stiffness transient elastography with ultrasound would improve the prediction of the development of a nodular liver on ultrasound and development of portal hypertension over time in children and young adults with CF. Study visits occurred at baseline and for at least two annual follow-up visits. 

This study is an ancillary study to the CFLD PUSH study. If requesting access to the ELASTIC-CF data, it is recommended to also request access to the CFLD PUSH data to obtain comprehensive information collected on study participants.
DOI: 10.58020/eqrt-bx74
title: Nonalcoholic Fatty Liver Disease Adult Database 2

description: Nonalcoholic fatty liver disease (NAFLD) is a spectrum of liver conditions that can progress to significant fibrosis and cirrhosis. There are an estimated 40-90 million individuals within the United States with NAFLD, 10- 30% of whom have NASH and may develop NASH-related cirrhosis. Identifying through non- invasive means those individuals who are at risk for progressive liver disease remains challenging.

The Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN) was initiated by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) in 2002 to conduct multicenter, collaborative studies on the etiology, contributing factors, natural history, complications and treatment of NASH. 

The NAFLD Adult Database 2 continued the longitudinal follow-up of participants enrolled in earlier NASH CRN studies and recruited new participants with recent liver biopsies. Comprehensive data, including demographics, medical history, symptoms, medication use, alcohol use and routine laboratory studies were collected on all participants at entry and at annual visits for up to 10 years after enrollment. A liver biopsy was collected at baseline if not collected in a prior NASH CRN study. Study questionnaires administered at enrollment included Skinner Lifetime Drinking history, Alcohol Use Disorders Identification Test (AUDIT) and Beverage Questionnaire (BEVQ-15). 

Specimens were collected every 48 weeks during follow-up. If liver biopsies were obtained as part of routine patient care, they were scored using the NASH CRN NAFLD Activity Score (NAS) and fibrosis score. The Interim drinking history (AUDIT-C) and BEVQ-15 were collected at follow-up visits.